JPH09500788A - Ｂ７−２：ｃｔｌａ４／ｃｄ２８カウンターレセプター - Google Patents

Info

Publication number

JPH09500788A

JPH09500788A JP7505397A JP50539795A JPH09500788A JP H09500788 A JPH09500788 A JP H09500788A JP 7505397 A JP7505397 A JP 7505397A JP 50539795 A JP50539795 A JP 50539795A JP H09500788 A JPH09500788 A JP H09500788A

Authority

JP

Japan

Prior art keywords

peptide

cells

cell

nucleic acid

protein

Prior art date

1993-07-26

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 title claims abstract description 66
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 title claims abstract description 66
• 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 title claims abstract description 64
• 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 title claims abstract description 62
• 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 322
• 210000004027 cell Anatomy 0.000 claims abstract description 294
• 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 255
• 108090000623 proteins and genes Proteins 0.000 claims abstract description 213
• 150000007523 nucleic acids Chemical class 0.000 claims abstract description 204
• 102000039446 nucleic acids Human genes 0.000 claims abstract description 182
• 108020004707 nucleic acids Proteins 0.000 claims abstract description 182
• 102000004169 proteins and genes Human genes 0.000 claims abstract description 172
• 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 82
• 239000002773 nucleotide Substances 0.000 claims abstract description 55
• 125000003729 nucleotide group Chemical group 0.000 claims abstract description 55
• 239000003446 ligand Substances 0.000 claims abstract description 51
• 239000013604 expression vector Substances 0.000 claims abstract description 42
• 108020004414 DNA Proteins 0.000 claims abstract description 18
• 230000021633 leukocyte mediated immunity Effects 0.000 claims abstract description 15
• 101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 claims abstract description 7
• 102100034924 T-lymphocyte activation antigen CD86 Human genes 0.000 claims abstract description 7
• 210000004881 tumor cell Anatomy 0.000 claims description 289
• 238000000034 method Methods 0.000 claims description 186
• 230000000694 effects Effects 0.000 claims description 177
• 230000014509 gene expression Effects 0.000 claims description 158
• 241000282414 Homo sapiens Species 0.000 claims description 148
• 101000718019 Homo sapiens A-kinase anchor protein 17A Proteins 0.000 claims description 108
• 102100026445 A-kinase anchor protein 17A Human genes 0.000 claims description 107
• 206010028980 Neoplasm Diseases 0.000 claims description 104
• 125000000539 amino acid group Chemical group 0.000 claims description 96
• 230000027455 binding Effects 0.000 claims description 70
• 102000037865 fusion proteins Human genes 0.000 claims description 68
• 108020001507 fusion proteins Proteins 0.000 claims description 68
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 67
• 239000002299 complementary DNA Substances 0.000 claims description 66
• 108091054438 MHC class II family Proteins 0.000 claims description 61
• 102000043131 MHC class II family Human genes 0.000 claims description 60
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 55
• 238000009739 binding Methods 0.000 claims description 54
• 230000000139 costimulatory effect Effects 0.000 claims description 53
• 150000001413 amino acids Chemical class 0.000 claims description 44
• 230000006870 function Effects 0.000 claims description 44
• 230000004913 activation Effects 0.000 claims description 42
• 102000004127 Cytokines Human genes 0.000 claims description 41
• 108090000695 Cytokines Proteins 0.000 claims description 41
• 108020004999 messenger RNA Proteins 0.000 claims description 41
• 210000002865 immune cell Anatomy 0.000 claims description 39
• 102000007697 B7-2 Antigen Human genes 0.000 claims description 38
• 230000035755 proliferation Effects 0.000 claims description 38
• 108010021800 B7-2 Antigen Proteins 0.000 claims description 37
• 230000006052 T cell proliferation Effects 0.000 claims description 35
• 230000028327 secretion Effects 0.000 claims description 35
• 241001465754 Metazoa Species 0.000 claims description 34
• 238000001727 in vivo Methods 0.000 claims description 33
• 239000000203 mixture Substances 0.000 claims description 33
• 238000004519 manufacturing process Methods 0.000 claims description 29
• 238000001890 transfection Methods 0.000 claims description 29
• 230000028993 immune response Effects 0.000 claims description 28
• 239000002253 acid Substances 0.000 claims description 26
• 230000004048 modification Effects 0.000 claims description 25
• 238000012986 modification Methods 0.000 claims description 25
• 108091054437 MHC class I family Proteins 0.000 claims description 23
• 238000000338 in vitro Methods 0.000 claims description 21
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
• 239000003814 drug Substances 0.000 claims description 20
• 230000001939 inductive effect Effects 0.000 claims description 20
• 239000013612 plasmid Substances 0.000 claims description 20
• 239000003795 chemical substances by application Substances 0.000 claims description 19
• 230000004927 fusion Effects 0.000 claims description 19
• 238000003259 recombinant expression Methods 0.000 claims description 19
• 230000000638 stimulation Effects 0.000 claims description 19
• 102000043129 MHC class I family Human genes 0.000 claims description 18
• 229940079593 drug Drugs 0.000 claims description 18
• 230000002401 inhibitory effect Effects 0.000 claims description 18
• 230000003993 interaction Effects 0.000 claims description 18
• 230000001404 mediated effect Effects 0.000 claims description 18
• 210000004408 hybridoma Anatomy 0.000 claims description 17
• 230000004940 costimulation Effects 0.000 claims description 16
• 230000004044 response Effects 0.000 claims description 16
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims description 15
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims description 15
• 210000001519 tissue Anatomy 0.000 claims description 15
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
• 230000001105 regulatory effect Effects 0.000 claims description 12
• 239000002609 medium Substances 0.000 claims description 11
• 230000009261 transgenic effect Effects 0.000 claims description 11
• 208000009329 Graft vs Host Disease Diseases 0.000 claims description 10
• 108060003951 Immunoglobulin Proteins 0.000 claims description 10
• 230000000259 anti-tumor effect Effects 0.000 claims description 10
• 208000024908 graft versus host disease Diseases 0.000 claims description 10
• 102000018358 immunoglobulin Human genes 0.000 claims description 10
• 230000004936 stimulating effect Effects 0.000 claims description 10
• 208000023275 Autoimmune disease Diseases 0.000 claims description 9
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 9
• 206010025323 Lymphomas Diseases 0.000 claims description 9
• 239000012636 effector Substances 0.000 claims description 9
• 108091026890 Coding region Proteins 0.000 claims description 8
• 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims description 8
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 8
• 230000000692 anti-sense effect Effects 0.000 claims description 8
• 230000016396 cytokine production Effects 0.000 claims description 8
• 238000010166 immunofluorescence Methods 0.000 claims description 8
• 201000001441 melanoma Diseases 0.000 claims description 8
• 244000052769 pathogen Species 0.000 claims description 8
• 238000006467 substitution reaction Methods 0.000 claims description 8
• 206010020751 Hypersensitivity Diseases 0.000 claims description 7
• 238000012217 deletion Methods 0.000 claims description 7
• 230000037430 deletion Effects 0.000 claims description 7
• 239000003937 drug carrier Substances 0.000 claims description 7
• 239000001963 growth medium Substances 0.000 claims description 7
• 230000010799 Receptor Interactions Effects 0.000 claims description 6
• 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 6
• 238000009396 hybridization Methods 0.000 claims description 6
• 208000032839 leukemia Diseases 0.000 claims description 6
• 210000000056 organ Anatomy 0.000 claims description 6
• 201000009030 Carcinoma Diseases 0.000 claims description 5
• 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 claims description 5
• 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 claims description 5
• 206010029260 Neuroblastoma Diseases 0.000 claims description 5
• 206010039491 Sarcoma Diseases 0.000 claims description 5
• 241000700605 Viruses Species 0.000 claims description 5
• 230000003213 activating effect Effects 0.000 claims description 5
• 210000004899 c-terminal region Anatomy 0.000 claims description 5
• 230000001413 cellular effect Effects 0.000 claims description 5
• 229960003444 immunosuppressant agent Drugs 0.000 claims description 5
• 239000003018 immunosuppressive agent Substances 0.000 claims description 5
• 230000031146 intracellular signal transduction Effects 0.000 claims description 5
• 230000001717 pathogenic effect Effects 0.000 claims description 5
• 102000006395 Globulins Human genes 0.000 claims description 4
• 108010044091 Globulins Proteins 0.000 claims description 4
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 4
• 241001024304 Mino Species 0.000 claims description 4
• 230000020385 T cell costimulation Effects 0.000 claims description 4
• 206010052779 Transplant rejections Diseases 0.000 claims description 4
• 230000007815 allergy Effects 0.000 claims description 4
• 239000006143 cell culture medium Substances 0.000 claims description 4
• 238000012258 culturing Methods 0.000 claims description 4
• 238000009472 formulation Methods 0.000 claims description 4
• 239000000463 material Substances 0.000 claims description 4
• 239000007787 solid Substances 0.000 claims description 4
• 230000024932 T cell mediated immunity Effects 0.000 claims description 3
• 230000002950 deficient Effects 0.000 claims description 3
• 230000002519 immonomodulatory effect Effects 0.000 claims description 3
• 230000004068 intracellular signaling Effects 0.000 claims description 3
• 210000004698 lymphocyte Anatomy 0.000 claims description 3
• 108010091748 peptide A Proteins 0.000 claims description 3
• 239000011574 phosphorus Substances 0.000 claims description 3
• 229910052698 phosphorus Inorganic materials 0.000 claims description 3
• 239000003981 vehicle Substances 0.000 claims description 3
• 206010012601 diabetes mellitus Diseases 0.000 claims description 2
• 230000001861 immunosuppressant effect Effects 0.000 claims description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
• 108010028930 invariant chain Proteins 0.000 claims 6
• 102000009109 Fc receptors Human genes 0.000 claims 4
• 108010087819 Fc receptors Proteins 0.000 claims 4
• 102000015736 beta 2-Microglobulin Human genes 0.000 claims 4
• 230000024203 complement activation Effects 0.000 claims 4
• 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
• 241000087624 Monoclona Species 0.000 claims 1
• 206010003549 asthenia Diseases 0.000 claims 1
• 239000002955 immunomodulating agent Substances 0.000 claims 1
• 229940121354 immunomodulator Drugs 0.000 claims 1
• 230000002584 immunomodulator Effects 0.000 claims 1
• 201000006417 multiple sclerosis Diseases 0.000 claims 1
• 210000003205 muscle Anatomy 0.000 claims 1
• 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
• 210000003719 b-lymphocyte Anatomy 0.000 abstract description 167
• 108091007433 antigens Proteins 0.000 abstract description 114
• 102000036639 antigens Human genes 0.000 abstract description 114
• 239000000427 antigen Substances 0.000 abstract description 112
• 230000006044 T cell activation Effects 0.000 abstract description 11
• 102000053602 DNA Human genes 0.000 abstract description 9
• 241000238631 Hexapoda Species 0.000 abstract description 5
• 238000004113 cell culture Methods 0.000 abstract description 5
• 210000003527 eukaryotic cell Anatomy 0.000 abstract description 3
• 235000018102 proteins Nutrition 0.000 description 125
• 239000013598 vector Substances 0.000 description 56
• 108700018351 Major Histocompatibility Complex Proteins 0.000 description 55
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 54
• 108010002350 Interleukin-2 Proteins 0.000 description 50
• 102000000588 Interleukin-2 Human genes 0.000 description 50
• 235000001014 amino acid Nutrition 0.000 description 47
• 229940024606 amino acid Drugs 0.000 description 46
• 230000000903 blocking effect Effects 0.000 description 33
• 239000000126 substance Substances 0.000 description 27
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 25
• 239000012634 fragment Substances 0.000 description 25
• 238000011282 treatment Methods 0.000 description 23
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
• 230000006698 induction Effects 0.000 description 19
• 230000004073 interleukin-2 production Effects 0.000 description 19
• 239000000243 solution Substances 0.000 description 19
• 230000001965 increasing effect Effects 0.000 description 18
• 108020003175 receptors Proteins 0.000 description 18
• 102000005962 receptors Human genes 0.000 description 18
• 230000003393 splenic effect Effects 0.000 description 18
• 241001529936 Murinae Species 0.000 description 17
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 17
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 17
• 201000011510 cancer Diseases 0.000 description 17
• 238000004132 cross linking Methods 0.000 description 17
• 241000894007 species Species 0.000 description 17
• 241000699666 Mus <mouse, genus> Species 0.000 description 16
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 16
• 239000003153 chemical reaction reagent Substances 0.000 description 16
• 150000001875 compounds Chemical class 0.000 description 16
• 238000005516 engineering process Methods 0.000 description 16
• 238000003556 assay Methods 0.000 description 15
• 230000001225 therapeutic effect Effects 0.000 description 15
• 241000699670 Mus sp. Species 0.000 description 14
• 238000004458 analytical method Methods 0.000 description 13
• 238000006243 chemical reaction Methods 0.000 description 13
• 241000588724 Escherichia coli Species 0.000 description 12
• 210000000612 antigen-presenting cell Anatomy 0.000 description 12
• 230000001086 cytosolic effect Effects 0.000 description 12
• 210000000952 spleen Anatomy 0.000 description 12
• 102100034343 Integrase Human genes 0.000 description 11
• 230000005867 T cell response Effects 0.000 description 11
• 238000013459 approach Methods 0.000 description 11
• 238000000684 flow cytometry Methods 0.000 description 11
• 230000036039 immunity Effects 0.000 description 11
• 210000004962 mammalian cell Anatomy 0.000 description 11
• 229940104230 thymidine Drugs 0.000 description 11
• 238000013518 transcription Methods 0.000 description 11
• 230000035897 transcription Effects 0.000 description 11
• 241000282412 Homo Species 0.000 description 10
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
• 238000010367 cloning Methods 0.000 description 10
• 201000010099 disease Diseases 0.000 description 10
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
• 230000037361 pathway Effects 0.000 description 10
• 239000013615 primer Substances 0.000 description 10
• 238000012163 sequencing technique Methods 0.000 description 10
• 238000002965 ELISA Methods 0.000 description 9
• 102000004388 Interleukin-4 Human genes 0.000 description 9
• 108090000978 Interleukin-4 Proteins 0.000 description 9
• 108091034117 Oligonucleotide Proteins 0.000 description 9
• 206010035226 Plasma cell myeloma Diseases 0.000 description 9
• 239000007983 Tris buffer Substances 0.000 description 9
• 150000007513 acids Chemical class 0.000 description 9
• 239000011324 bead Substances 0.000 description 9
• 238000002474 experimental method Methods 0.000 description 9
• 230000003053 immunization Effects 0.000 description 9
• 230000005847 immunogenicity Effects 0.000 description 9
• 229940028885 interleukin-4 Drugs 0.000 description 9
• 201000000050 myeloid neoplasm Diseases 0.000 description 9
• 238000000746 purification Methods 0.000 description 9
• 238000010561 standard procedure Methods 0.000 description 9
• 238000012546 transfer Methods 0.000 description 9
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
• 206010011968 Decreased immune responsiveness Diseases 0.000 description 8
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 8
• 108091034057 RNA (poly(A)) Proteins 0.000 description 8
• 230000005809 anti-tumor immunity Effects 0.000 description 8
• 230000000890 antigenic effect Effects 0.000 description 8
• 210000001185 bone marrow Anatomy 0.000 description 8
• 238000010276 construction Methods 0.000 description 8
• -1 if used Substances 0.000 description 8
• 230000001506 immunosuppresive effect Effects 0.000 description 8
• 230000005764 inhibitory process Effects 0.000 description 8
• PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 8
• 230000014616 translation Effects 0.000 description 8
• 230000003612 virological effect Effects 0.000 description 8
• 108700028369 Alleles Proteins 0.000 description 7
• 230000003844 B-cell-activation Effects 0.000 description 7
• 241000283707 Capra Species 0.000 description 7
• 108020004705 Codon Proteins 0.000 description 7
• 241000124008 Mammalia Species 0.000 description 7
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 7
• 230000015572 biosynthetic process Effects 0.000 description 7
• 239000002981 blocking agent Substances 0.000 description 7
• 210000004369 blood Anatomy 0.000 description 7
• 239000008280 blood Substances 0.000 description 7
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
• 235000018417 cysteine Nutrition 0.000 description 7
• 238000002649 immunization Methods 0.000 description 7
• 238000011534 incubation Methods 0.000 description 7
• 238000002955 isolation Methods 0.000 description 7
• 238000003752 polymerase chain reaction Methods 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• 230000009257 reactivity Effects 0.000 description 7
• 238000010839 reverse transcription Methods 0.000 description 7
• 238000012216 screening Methods 0.000 description 7
• 239000011780 sodium chloride Substances 0.000 description 7
• 239000006228 supernatant Substances 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 239000013603 viral vector Substances 0.000 description 7
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
• 108010076504 Protein Sorting Signals Proteins 0.000 description 6
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
• 108700019146 Transgenes Proteins 0.000 description 6
• 238000007792 addition Methods 0.000 description 6
• 230000002708 enhancing effect Effects 0.000 description 6
• 230000012010 growth Effects 0.000 description 6
• 230000002163 immunogen Effects 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
• 229910001629 magnesium chloride Inorganic materials 0.000 description 6
• 239000003550 marker Substances 0.000 description 6
• 210000001616 monocyte Anatomy 0.000 description 6
• 230000035772 mutation Effects 0.000 description 6
• 210000000822 natural killer cell Anatomy 0.000 description 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
• 229920002307 Dextran Polymers 0.000 description 5
• 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 5
• 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 5
• 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 5
• 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 5
• 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 5
• 206010062016 Immunosuppression Diseases 0.000 description 5
• 108700005092 MHC Class II Genes Proteins 0.000 description 5
• 238000000636 Northern blotting Methods 0.000 description 5
• 108700026244 Open Reading Frames Proteins 0.000 description 5
• 108010033276 Peptide Fragments Proteins 0.000 description 5
• 102000007079 Peptide Fragments Human genes 0.000 description 5
• 241000700159 Rattus Species 0.000 description 5
• 108091023040 Transcription factor Proteins 0.000 description 5
• 102000040945 Transcription factor Human genes 0.000 description 5
• 235000004279 alanine Nutrition 0.000 description 5
• 230000006023 anti-tumor response Effects 0.000 description 5
• AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Inorganic materials [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 5
• RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 5
• HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 5
• 230000007423 decrease Effects 0.000 description 5
• 238000001514 detection method Methods 0.000 description 5
• 230000029087 digestion Effects 0.000 description 5
• 239000012894 fetal calf serum Substances 0.000 description 5
• 238000010348 incorporation Methods 0.000 description 5
• 208000015181 infectious disease Diseases 0.000 description 5
• 230000036210 malignancy Effects 0.000 description 5
• 239000011259 mixed solution Substances 0.000 description 5
• 238000010369 molecular cloning Methods 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 230000002265 prevention Effects 0.000 description 5
• 230000000284 resting effect Effects 0.000 description 5
• 238000000926 separation method Methods 0.000 description 5
• 238000010186 staining Methods 0.000 description 5
• 230000009885 systemic effect Effects 0.000 description 5
• 238000013519 translation Methods 0.000 description 5
• 238000002054 transplantation Methods 0.000 description 5
• 241000894006 Bacteria Species 0.000 description 4
• 101710203526 Integrase Proteins 0.000 description 4
• 108010052285 Membrane Proteins Proteins 0.000 description 4
• 108020004511 Recombinant DNA Proteins 0.000 description 4
• 108091008874 T cell receptors Proteins 0.000 description 4
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
• 238000009825 accumulation Methods 0.000 description 4
• 230000000735 allogeneic effect Effects 0.000 description 4
• 230000003321 amplification Effects 0.000 description 4
• 239000000074 antisense oligonucleotide Substances 0.000 description 4
• 238000012230 antisense oligonucleotides Methods 0.000 description 4
• 230000009286 beneficial effect Effects 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
• NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 4
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 210000003162 effector t lymphocyte Anatomy 0.000 description 4
• 238000001415 gene therapy Methods 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 229960002743 glutamine Drugs 0.000 description 4
• PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
• 238000001114 immunoprecipitation Methods 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 210000002540 macrophage Anatomy 0.000 description 4
• 230000005291 magnetic effect Effects 0.000 description 4
• 239000012528 membrane Substances 0.000 description 4
• 229960004857 mitomycin Drugs 0.000 description 4
• 238000003199 nucleic acid amplification method Methods 0.000 description 4
• 239000002644 phorbol ester Substances 0.000 description 4
• 239000002953 phosphate buffered saline Substances 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 239000000843 powder Substances 0.000 description 4
• 230000002829 reductive effect Effects 0.000 description 4
• 230000010076 replication Effects 0.000 description 4
• 239000000523 sample Substances 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 230000003248 secreting effect Effects 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 238000012360 testing method Methods 0.000 description 4
• 230000014621 translational initiation Effects 0.000 description 4
• 210000004885 white matter Anatomy 0.000 description 4
• QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 3
• RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 3
• 208000030507 AIDS Diseases 0.000 description 3
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
• 208000011691 Burkitt lymphomas Diseases 0.000 description 3
• 102000014914 Carrier Proteins Human genes 0.000 description 3
• 108020004635 Complementary DNA Proteins 0.000 description 3
• 241000699800 Cricetinae Species 0.000 description 3
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
• 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
• 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
• 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 3
• 101150062179 II gene Proteins 0.000 description 3
• 108700005089 MHC Class I Genes Proteins 0.000 description 3
• 206010027476 Metastases Diseases 0.000 description 3
• 101150076359 Mhc gene Proteins 0.000 description 3
• 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
• 230000004988 N-glycosylation Effects 0.000 description 3
• 229930040373 Paraformaldehyde Natural products 0.000 description 3
• 229930182555 Penicillin Natural products 0.000 description 3
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 239000012980 RPMI-1640 medium Substances 0.000 description 3
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
• 208000025865 Ulcer Diseases 0.000 description 3
• 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
• 108091008324 binding proteins Proteins 0.000 description 3
• 230000005540 biological transmission Effects 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 3
• 229960005263 bucladesine Drugs 0.000 description 3
• 230000003915 cell function Effects 0.000 description 3
• 239000006285 cell suspension Substances 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 238000012512 characterization method Methods 0.000 description 3
• 210000000349 chromosome Anatomy 0.000 description 3
• 230000000295 complement effect Effects 0.000 description 3
• 238000007796 conventional method Methods 0.000 description 3
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
• 210000000805 cytoplasm Anatomy 0.000 description 3
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 210000004443 dendritic cell Anatomy 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• 230000018109 developmental process Effects 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 239000002270 dispersing agent Substances 0.000 description 3
• 239000002612 dispersion medium Substances 0.000 description 3
• 230000003828 downregulation Effects 0.000 description 3
• 238000004520 electroporation Methods 0.000 description 3
• 239000003623 enhancer Substances 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• 238000000605 extraction Methods 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 230000013595 glycosylation Effects 0.000 description 3
• 238000006206 glycosylation reaction Methods 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 230000002452 interceptive effect Effects 0.000 description 3
• 238000001990 intravenous administration Methods 0.000 description 3
• 210000002510 keratinocyte Anatomy 0.000 description 3
• 230000007774 longterm Effects 0.000 description 3
• 210000002751 lymph Anatomy 0.000 description 3
• 230000009401 metastasis Effects 0.000 description 3
• 210000005087 mononuclear cell Anatomy 0.000 description 3
• 210000001672 ovary Anatomy 0.000 description 3
• 238000004091 panning Methods 0.000 description 3
• 229920002866 paraformaldehyde Polymers 0.000 description 3
• 229940049954 penicillin Drugs 0.000 description 3
• 210000005259 peripheral blood Anatomy 0.000 description 3
• 239000011886 peripheral blood Substances 0.000 description 3
• 239000012071 phase Substances 0.000 description 3
• QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 3
• PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
• 239000004033 plastic Substances 0.000 description 3
• 229920003023 plastic Polymers 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 230000008569 process Effects 0.000 description 3
• 238000001742 protein purification Methods 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 238000001228 spectrum Methods 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 231100000397 ulcer Toxicity 0.000 description 3
• 241000701161 unidentified adenovirus Species 0.000 description 3
• 230000003827 upregulation Effects 0.000 description 3
• 238000002255 vaccination Methods 0.000 description 3
• 229910052720 vanadium Inorganic materials 0.000 description 3
• LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 2
• WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 2
• GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
• 239000005695 Ammonium acetate Substances 0.000 description 2
• 102100034613 Annexin A2 Human genes 0.000 description 2
• 108090000668 Annexin A2 Proteins 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 2
• 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 2
• 208000012526 B-cell neoplasm Diseases 0.000 description 2
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
• 102100027314 Beta-2-microglobulin Human genes 0.000 description 2
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
• 241000283690 Bos taurus Species 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 206010009944 Colon cancer Diseases 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• 229930105110 Cyclosporin A Natural products 0.000 description 2
• 108010036949 Cyclosporine Proteins 0.000 description 2
• 102000012410 DNA Ligases Human genes 0.000 description 2
• 108010061982 DNA Ligases Proteins 0.000 description 2
• 239000003155 DNA primer Substances 0.000 description 2
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
• 101710204837 Envelope small membrane protein Proteins 0.000 description 2
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 2
• 208000036566 Erythroleukaemia Diseases 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 241000724791 Filamentous phage Species 0.000 description 2
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
• 101150087426 Gnal gene Proteins 0.000 description 2
• 208000005176 Hepatitis C Diseases 0.000 description 2
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
• 108090000144 Human Proteins Proteins 0.000 description 2
• 102000003839 Human Proteins Human genes 0.000 description 2
• 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
• 102000008070 Interferon-gamma Human genes 0.000 description 2
• 108010074328 Interferon-gamma Proteins 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
• 241000406668 Loxodonta cyclotis Species 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 241000282376 Panthera tigris Species 0.000 description 2
• 108091005804 Peptidases Proteins 0.000 description 2
• 102000035195 Peptidases Human genes 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• 208000007452 Plasmacytoma Diseases 0.000 description 2
• 239000004698 Polyethylene Substances 0.000 description 2
• 101710088839 Replication initiation protein Proteins 0.000 description 2
• 108091081021 Sense strand Proteins 0.000 description 2
• 108010067390 Viral Proteins Proteins 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
• NFXWJYUDIOHFAW-UHFFFAOYSA-N acetic acid;tetradecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCC(O)=O NFXWJYUDIOHFAW-UHFFFAOYSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 208000021841 acute erythroid leukemia Diseases 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 239000011543 agarose gel Substances 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 230000000961 alloantigen Effects 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 229940043376 ammonium acetate Drugs 0.000 description 2
• 235000019257 ammonium acetate Nutrition 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000005875 antibody response Effects 0.000 description 2
• 230000007416 antiviral immune response Effects 0.000 description 2
• 239000012062 aqueous buffer Substances 0.000 description 2
• 210000001130 astrocyte Anatomy 0.000 description 2
• 230000001580 bacterial effect Effects 0.000 description 2
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 238000001574 biopsy Methods 0.000 description 2
• 229940098773 bovine serum albumin Drugs 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 238000010804 cDNA synthesis Methods 0.000 description 2
• 239000001506 calcium phosphate Substances 0.000 description 2
• 229910000389 calcium phosphate Inorganic materials 0.000 description 2
• 235000011010 calcium phosphates Nutrition 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 229960001265 ciclosporin Drugs 0.000 description 2
• 238000004140 cleaning Methods 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 230000009089 cytolysis Effects 0.000 description 2
• 230000001461 cytolytic effect Effects 0.000 description 2
• 238000004163 cytometry Methods 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 230000002222 downregulating effect Effects 0.000 description 2
• 210000001671 embryonic stem cell Anatomy 0.000 description 2
• 210000002889 endothelial cell Anatomy 0.000 description 2
• 239000002532 enzyme inhibitor Substances 0.000 description 2
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 238000001400 expression cloning Methods 0.000 description 2
• 239000000835 fiber Substances 0.000 description 2
• 210000002950 fibroblast Anatomy 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
• 235000011187 glycerol Nutrition 0.000 description 2
• ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 2
• 239000000833 heterodimer Substances 0.000 description 2
• 238000002744 homologous recombination Methods 0.000 description 2
• 230000006801 homologous recombination Effects 0.000 description 2
• 102000043321 human CTLA4 Human genes 0.000 description 2
• 230000002998 immunogenetic effect Effects 0.000 description 2
• 238000009169 immunotherapy Methods 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• 206010022000 influenza Diseases 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 230000010189 intracellular transport Effects 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007912 intraperitoneal administration Methods 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 239000007951 isotonicity adjuster Substances 0.000 description 2
• 230000006651 lactation Effects 0.000 description 2
• 210000001821 langerhans cell Anatomy 0.000 description 2
• 210000001161 mammalian embryo Anatomy 0.000 description 2
• 230000001394 metastastic effect Effects 0.000 description 2
• 206010061289 metastatic neoplasm Diseases 0.000 description 2
• 229930182817 methionine Natural products 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 230000007896 negative regulation of T cell activation Effects 0.000 description 2
• 230000001613 neoplastic effect Effects 0.000 description 2
• BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 210000004248 oligodendroglia Anatomy 0.000 description 2
• 230000036961 partial effect Effects 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 229960003742 phenol Drugs 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 229920000573 polyethylene Polymers 0.000 description 2
• 102000054765 polymorphisms of proteins Human genes 0.000 description 2
• 229920001184 polypeptide Polymers 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 230000002062 proliferating effect Effects 0.000 description 2
• 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 108091008146 restriction endonucleases Proteins 0.000 description 2
• 201000006845 reticulosarcoma Diseases 0.000 description 2
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 238000007423 screening assay Methods 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
• 229940063673 spermidine Drugs 0.000 description 2
• 238000007447 staining method Methods 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 229960002385 streptomycin sulfate Drugs 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 230000002123 temporal effect Effects 0.000 description 2
• 230000004797 therapeutic response Effects 0.000 description 2
• 230000024664 tolerance induction Effects 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• 230000010474 transient expression Effects 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 241000701447 unidentified baculovirus Species 0.000 description 2
• 229960005486 vaccine Drugs 0.000 description 2
• 230000029812 viral genome replication Effects 0.000 description 2
• 239000002023 wood Substances 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 1
• FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
• 150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• 108010039627 Aprotinin Proteins 0.000 description 1
• 206010003445 Ascites Diseases 0.000 description 1
• 101100136076 Aspergillus oryzae (strain ATCC 42149 / RIB 40) pel1 gene Proteins 0.000 description 1
• 206010003645 Atopy Diseases 0.000 description 1
• 208000030767 Autoimmune encephalitis Diseases 0.000 description 1
• 101150089247 B7 gene Proteins 0.000 description 1
• 108010035053 B7-1 Antigen Proteins 0.000 description 1
• 102000038504 B7-1 Antigen Human genes 0.000 description 1
• 206010006187 Breast cancer Diseases 0.000 description 1
• 208000026310 Breast neoplasm Diseases 0.000 description 1
• 210000003771 C cell Anatomy 0.000 description 1
• 101710117545 C protein Proteins 0.000 description 1
• 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
• 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
• 101100290380 Caenorhabditis elegans cel-1 gene Proteins 0.000 description 1
• 101100408682 Caenorhabditis elegans pmt-2 gene Proteins 0.000 description 1
• 101100095796 Caenorhabditis elegans sig-7 gene Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• CXRFDZFCGOPDTD-UHFFFAOYSA-M Cetrimide Chemical compound [Br-].CCCCCCCCCCCCCC[N+](C)(C)C CXRFDZFCGOPDTD-UHFFFAOYSA-M 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 102000029816 Collagenase Human genes 0.000 description 1
• 108060005980 Collagenase Proteins 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 241000701022 Cytomegalovirus Species 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 150000008574 D-amino acids Chemical class 0.000 description 1
• 102000004594 DNA Polymerase I Human genes 0.000 description 1
• 108010017826 DNA Polymerase I Proteins 0.000 description 1
• 108020003215 DNA Probes Proteins 0.000 description 1
• 239000003298 DNA probe Substances 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 101100096502 Danio rerio spring gene Proteins 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 206010059866 Drug resistance Diseases 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 102100031780 Endonuclease Human genes 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
• 241001288713 Escherichia coli MC1061 Species 0.000 description 1
• 241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 1
• 241000206602 Eukaryota Species 0.000 description 1
• 206010051841 Exposure to allergen Diseases 0.000 description 1
• 108010074860 Factor Xa Proteins 0.000 description 1
• 238000005740 Freeman reaction Methods 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 206010071602 Genetic polymorphism Diseases 0.000 description 1
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
• 102000005720 Glutathione transferase Human genes 0.000 description 1
• 108010070675 Glutathione transferase Proteins 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 208000031886 HIV Infections Diseases 0.000 description 1
• 102000006354 HLA-DR Antigens Human genes 0.000 description 1
• 108010058597 HLA-DR Antigens Proteins 0.000 description 1
• 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
• 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 description 1
• 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 102100022338 Integrin alpha-M Human genes 0.000 description 1
• 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 108010002586 Interleukin-7 Proteins 0.000 description 1
• 108010002335 Interleukin-9 Proteins 0.000 description 1
• 108010076876 Keratins Proteins 0.000 description 1
• 102000011782 Keratins Human genes 0.000 description 1
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 241001077660 Molo Species 0.000 description 1
• 108090000143 Mouse Proteins Proteins 0.000 description 1
• 101100438951 Mus musculus Cd86 gene Proteins 0.000 description 1
• 101100096504 Mus musculus Spring1 gene Proteins 0.000 description 1
• TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
• 235000021360 Myristic acid Nutrition 0.000 description 1
• 241001553014 Myrsine salicina Species 0.000 description 1
• AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
• 108091092724 Noncoding DNA Proteins 0.000 description 1
• 101710163270 Nuclease Proteins 0.000 description 1
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
• 108091005461 Nucleic proteins Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 101710126321 Pancreatic trypsin inhibitor Proteins 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 241000282520 Papio Species 0.000 description 1
• 241001504519 Papio ursinus Species 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 241000577979 Peromyscus spicilegus Species 0.000 description 1
• 108091000080 Phosphotransferase Proteins 0.000 description 1
• 108010047620 Phytohemagglutinins Proteins 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 101710118538 Protease Proteins 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 101100426090 Rattus norvegicus Trim9 gene Proteins 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 241000555745 Sciuridae Species 0.000 description 1
• 206010070834 Sensitisation Diseases 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 241000409492 Simian enterovirus SV4 Species 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
• 229910052776 Thorium Inorganic materials 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 241000711517 Torovirus Species 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
• 101150117115 V gene Proteins 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 208000012544 Viral Skin disease Diseases 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 108010006886 Vitrogen Proteins 0.000 description 1
• 101100096505 Xenopus laevis spring1 gene Proteins 0.000 description 1
• CJGYSWNGNKCJSB-YVLZZHOMSA-M [(4ar,6r,7r,7ar)-6-[6-(butanoylamino)purin-9-yl]-2-oxido-2-oxo-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-yl] butanoate Chemical compound C([C@H]1O2)OP([O-])(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-M 0.000 description 1
• HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
• 239000003070 absorption delaying agent Substances 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 230000010933 acylation Effects 0.000 description 1
• 238000005917 acylation reaction Methods 0.000 description 1
• 230000002776 aggregation Effects 0.000 description 1
• 238000004220 aggregation Methods 0.000 description 1
• 230000016571 aggressive behavior Effects 0.000 description 1
• 230000029936 alkylation Effects 0.000 description 1
• 238000005804 alkylation reaction Methods 0.000 description 1
• 239000013566 allergen Substances 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 208000030961 allergic reaction Diseases 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
• 230000002788 anti-peptide Effects 0.000 description 1
• 210000000628 antibody-producing cell Anatomy 0.000 description 1
• 239000003005 anticarcinogenic agent Substances 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 230000005975 antitumor immune response Effects 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 235000003704 aspartic acid Nutrition 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000005784 autoimmunity Effects 0.000 description 1
• VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1h-imidazol-2-yl)quinoline-3-carboxylate Chemical compound N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 description 1
• 230000037429 base substitution Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
• 210000002459 blastocyst Anatomy 0.000 description 1
• 201000000053 blastoma Diseases 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 239000006227 byproduct Substances 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 125000001314 canonical amino-acid group Chemical group 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000007910 cell fusion Effects 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 238000001516 cell proliferation assay Methods 0.000 description 1
• 230000007969 cellular immunity Effects 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 238000012412 chemical coupling Methods 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 210000000078 claw Anatomy 0.000 description 1
• 239000012459 cleaning agent Substances 0.000 description 1
• 238000000975 co-precipitation Methods 0.000 description 1
• 238000011278 co-treatment Methods 0.000 description 1
• 238000004581 coalescence Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 229960002424 collagenase Drugs 0.000 description 1
• 238000004440 column chromatography Methods 0.000 description 1
• 230000006957 competitive inhibition Effects 0.000 description 1
• 230000009918 complex formation Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 238000005336 cracking Methods 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 238000005034 decoration Methods 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• 238000000432 density-gradient centrifugation Methods 0.000 description 1
• 230000008021 deposition Effects 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 230000004069 differentiation Effects 0.000 description 1
• UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• 229940088679 drug related substance Drugs 0.000 description 1
• 238000004043 dyeing Methods 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 201000008184 embryoma Diseases 0.000 description 1
• 210000002308 embryonic cell Anatomy 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 206010014599 encephalitis Diseases 0.000 description 1
• 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
• 230000006862 enzymatic digestion Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229940125532 enzyme inhibitor Drugs 0.000 description 1
• 210000003386 epithelial cell of thymus gland Anatomy 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 210000003743 erythrocyte Anatomy 0.000 description 1
• 239000003797 essential amino acid Substances 0.000 description 1
• 235000020776 essential amino acid Nutrition 0.000 description 1
• 238000012869 ethanol precipitation Methods 0.000 description 1
• 239000002360 explosive Substances 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 230000008713 feedback mechanism Effects 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 238000010230 functional analysis Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 229940044627 gamma-interferon Drugs 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 238000012239 gene modification Methods 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 230000005017 genetic modification Effects 0.000 description 1
• 235000013617 genetically modified food Nutrition 0.000 description 1
• 210000004602 germ cell Anatomy 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 235000004554 glutamine Nutrition 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 239000001307 helium Substances 0.000 description 1
• 229910052734 helium Inorganic materials 0.000 description 1
• SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
• XMHIUKTWLZUKEX-UHFFFAOYSA-N hexacosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(O)=O XMHIUKTWLZUKEX-UHFFFAOYSA-N 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 229960002885 histidine Drugs 0.000 description 1
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
• 238000000265 homogenisation Methods 0.000 description 1
• 102000052301 human GNAZ Human genes 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 238000010185 immunofluorescence analysis Methods 0.000 description 1
• 238000003125 immunofluorescent labeling Methods 0.000 description 1
• 230000003308 immunostimulating effect Effects 0.000 description 1
• 230000002637 immunotoxin Effects 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 231100000608 immunotoxin Toxicity 0.000 description 1
• 229940051026 immunotoxin Drugs 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 230000017307 interleukin-4 production Effects 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000005342 ion exchange Methods 0.000 description 1
• 210000004153 islets of langerhan Anatomy 0.000 description 1
• 150000002540 isothiocyanates Chemical class 0.000 description 1
• 244000145841 kine Species 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 235000005772 leucine Nutrition 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 238000001638 lipofection Methods 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000005923 long-lasting effect Effects 0.000 description 1
• ZBJWWKFMHOAPNS-UHFFFAOYSA-N loretin Chemical compound C1=CN=C2C(O)=C(I)C=C(S(O)(=O)=O)C2=C1 ZBJWWKFMHOAPNS-UHFFFAOYSA-N 0.000 description 1
• 229950010248 loretin Drugs 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 201000004792 malaria Diseases 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 238000000520 microinjection Methods 0.000 description 1
• 239000011707 mineral Substances 0.000 description 1
• 235000010755 mineral Nutrition 0.000 description 1
• 230000002297 mitogenic effect Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 108091005601 modified peptides Proteins 0.000 description 1
• 102000035118 modified proteins Human genes 0.000 description 1
• 108091005573 modified proteins Proteins 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000025020 negative regulation of T cell proliferation Effects 0.000 description 1
• 230000012177 negative regulation of immune response Effects 0.000 description 1
• 239000002736 nonionic surfactant Substances 0.000 description 1
• 239000002853 nucleic acid probe Substances 0.000 description 1
• 239000002777 nucleoside Substances 0.000 description 1
• 150000003833 nucleoside derivatives Chemical class 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 101150040383 pel2 gene Proteins 0.000 description 1
• 101150050446 pelB gene Proteins 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 238000010647 peptide synthesis reaction Methods 0.000 description 1
• 210000004976 peripheral blood cell Anatomy 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 238000002823 phage display Methods 0.000 description 1
• 239000008194 pharmaceutical composition Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 150000004633 phorbol derivatives Chemical class 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 102000020233 phosphotransferase Human genes 0.000 description 1
• 230000001885 phytohemagglutinin Effects 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 239000002987 primer (paints) Substances 0.000 description 1
• 238000007639 printing Methods 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 229940107700 pyruvic acid Drugs 0.000 description 1
• 230000002285 radioactive effect Effects 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 230000001177 retroviral effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000007363 ring formation reaction Methods 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 229940016590 sarkosyl Drugs 0.000 description 1
• 108700004121 sarkosyl Proteins 0.000 description 1
• 201000004409 schistosomiasis Diseases 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000008313 sensitization Effects 0.000 description 1
• 235000004400 serine Nutrition 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229910052709 silver Inorganic materials 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000001632 sodium acetate Substances 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Substances [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 1
• 239000008279 sol Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 238000010532 solid phase synthesis reaction Methods 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000003068 static effect Effects 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 239000000021 stimulant Substances 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• NMGNJWORLGLLHQ-UHFFFAOYSA-M sulcofuron-sodium Chemical compound [Na+].[O-]S(=O)(=O)C1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 NMGNJWORLGLLHQ-UHFFFAOYSA-M 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 238000010998 test method Methods 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
• 229940033663 thimerosal Drugs 0.000 description 1
• 235000008521 threonine Nutrition 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 239000003053 toxin Substances 0.000 description 1
• 231100000765 toxin Toxicity 0.000 description 1
• 108700012359 toxins Proteins 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 238000011830 transgenic mouse model Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 229940108519 trasylol Drugs 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 241001515965 unidentified phage Species 0.000 description 1
• 241001430294 unidentified retrovirus Species 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 238000009777 vacuum freeze-drying Methods 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 239000011800 void material Substances 0.000 description 1
• 238000005406 washing Methods 0.000 description 1